NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Up 29.3% in March

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 290,900 shares, a growth of 29.3% from the March 15th total of 224,900 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily volume of 152,900 shares, the days-to-cover ratio is currently 1.9 days.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several institutional investors have recently bought and sold shares of NRSN. XTX Topco Ltd raised its position in shares of NeuroSense Therapeutics by 40.9% during the 3rd quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock valued at $58,000 after buying an additional 13,346 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics in the 4th quarter valued at approximately $78,000. Finally, Citadel Advisors LLC boosted its holdings in shares of NeuroSense Therapeutics by 640.9% in the 4th quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock worth $305,000 after purchasing an additional 219,717 shares during the period. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Price Performance

NRSN stock opened at $0.99 on Monday. The company has a market capitalization of $13.58 million, a price-to-earnings ratio of -1.55 and a beta of 1.36. NeuroSense Therapeutics has a 1-year low of $0.51 and a 1-year high of $1.50. The business has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.11.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings results on Monday, April 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.